{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:53Z","timestamp":1794048893375,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to describe the clinical features of lymphangioleiomyomatosis (LAM) in Korean patients and identify factors associated with progressive disease (PD). Clinical features of 54 patients with definite or probable LAM from 2005 to 2018 were retrospectively analysed. Common features were pneumothorax (66.7%) and abdominal lymphadenopathy (50.0%). Twenty-three (42.6%) patients were initially treated with mechanistic target of rapamycin (mTOR) inhibitors. Lung transplantation (LT) was performed in 13 (24.1%) patients. Grouped based on the annual decline in forced expiratory volume in 1\u00a0s (FEV<jats:sub>1<\/jats:sub>) from baseline and LT, 36 (66.7%) patients exhibited stable disease (SD). All six deaths (11.1%) occurred in PD. Proportion of SD was higher in those treated initially with mTOR inhibitors than in those under observation (<jats:italic>p<\/jats:italic>\u2009=\u20090.043). Univariate analysis revealed sirolimus use, and baseline forced vital capacity, FEV<jats:sub>1<\/jats:sub>, and diffusing capacity of the lungs for carbon monoxide are associated with PD. Multivariate analysis showed that only sirolimus use (odds ratio 0.141, 95% confidence interval 0.021\u20130.949, <jats:italic>p<\/jats:italic>\u2009=\u20090.044) reduced PD. Kaplan\u2013Meier analysis estimates overall survival of 92.0% and 74.7% at 5 and 10\u00a0years, respectively. A considerable proportion of LAM patients remain clinically stable without treatment. LT is an increasingly viable option for patients with severe lung function decline.<\/jats:p>","DOI":"10.1038\/s41598-022-12314-1","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T10:02:54Z","timestamp":1652868174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea"],"prefix":"10.1038","volume":"12","author":[{"given":"Shihwan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Soo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah Young","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Soo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Ye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Gu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Chae","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Sup","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"12314_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1183\/09031936.00076209","volume":"35","author":"SR Johnson","year":"2010","unstructured":"Johnson, S. R. et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur. Respir. J. 35, 14\u201326. https:\/\/doi.org\/10.1183\/09031936.00076209 (2010).","journal-title":"Eur. Respir. J."},{"key":"12314_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/lrb.2009.0024","volume":"8","author":"AM Taveira-DaSilva","year":"2010","unstructured":"Taveira-DaSilva, A. M., Pacheco-Rodriguez, G. & Moss, J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat. Res. Biol. 8, 9\u201319. https:\/\/doi.org\/10.1089\/lrb.2009.0024 (2010).","journal-title":"Lymphat. Res. Biol."},{"key":"12314_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.chest.2018.06.016","volume":"155","author":"N Gupta","year":"2019","unstructured":"Gupta, N. et al. The NHLBI LAM registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis. Chest 155, 288\u2013296. https:\/\/doi.org\/10.1016\/j.chest.2018.06.016 (2019).","journal-title":"Chest"},{"key":"12314_CR4","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2004.023283","volume":"59","author":"SR Johnson","year":"2004","unstructured":"Johnson, S. R., Whale, C. I., Hubbard, R. B., Lewis, S. A. & Tattersfield, A. E. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 59, 800\u2013803. https:\/\/doi.org\/10.1136\/thx.2004.023283 (2004).","journal-title":"Thorax"},{"key":"12314_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1440-1843.2007.01101.x","volume":"12","author":"M Hayashida","year":"2007","unstructured":"Hayashida, M. et al. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 12, 523\u2013530. https:\/\/doi.org\/10.1111\/j.1440-1843.2007.01101.x (2007).","journal-title":"Respirology"},{"key":"12314_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/thx.54.7.618","volume":"54","author":"YM Oh","year":"1999","unstructured":"Oh, Y. M. et al. Pulmonary lymphangioleiomyomatosis in Korea. Thorax 54, 618\u2013621. https:\/\/doi.org\/10.1136\/thx.54.7.618 (1999).","journal-title":"Thorax"},{"key":"12314_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3346\/jkms.2010.25.8.1182","volume":"25","author":"HY Park","year":"2010","unstructured":"Park, H. Y. et al. A nationwide survey of lymphangioleiomyomatosis in Korea: recent increase in newly diagnosed patients. J. Korean Med. Sci. 25, 1182\u20131186. https:\/\/doi.org\/10.3346\/jkms.2010.25.8.1182 (2010).","journal-title":"J. Korean Med. Sci."},{"key":"12314_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack, F. X. et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364, 1595\u20131606. https:\/\/doi.org\/10.1056\/NEJMoa1100391 (2011).","journal-title":"N. Engl. J. Med."},{"key":"12314_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/thoraxjnl-2017-210872","volume":"73","author":"J Bee","year":"2018","unstructured":"Bee, J., Fuller, S., Miller, S. & Johnson, S. R. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. Thorax 73, 369\u2013375. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210872 (2018).","journal-title":"Thorax"},{"key":"12314_CR10","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1513\/AnnalsATS.201605-335OC","volume":"13","author":"T Takada","year":"2016","unstructured":"Takada, T. et al. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. Ann. Am. Thorac. Soc. 13, 1912\u20131922. https:\/\/doi.org\/10.1513\/AnnalsATS.201605-335OC (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"12314_CR11","doi-asserted-by":"publisher","unstructured":"Taveira-DaSilva, A. M., Hathaway, O., Stylianou, M. & Moss, J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann. Intern. Med. 154, 797\u2013805, W-292\u2013793. https:\/\/doi.org\/10.7326\/0003-4819-154-12-201106210-00007 (2011).","DOI":"10.7326\/0003-4819-154-12-201106210-00007"},{"key":"12314_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1513\/AnnalsATS.201610-824OC","volume":"14","author":"C Lu","year":"2017","unstructured":"Lu, C. et al. A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis. Ann. Am. Thorac. Soc. 14, 919\u2013928. https:\/\/doi.org\/10.1513\/AnnalsATS.201610-824OC (2017).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"12314_CR13","doi-asserted-by":"publisher","first-page":"e0146749","DOI":"10.1371\/journal.pone.0146749","volume":"11","author":"K Ando","year":"2016","unstructured":"Ando, K. et al. Lung Transplantation for Lymphangioleiomyomatosis in Japan. PLoS ONE 11, e0146749. https:\/\/doi.org\/10.1371\/journal.pone.0146749 (2016).","journal-title":"PLoS ONE"},{"key":"12314_CR14","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.rmed.2015.08.014","volume":"109","author":"K Ussavarungsi","year":"2015","unstructured":"Ussavarungsi, K. et al. Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis. Respir. Med. 109, 1354\u20131359. https:\/\/doi.org\/10.1016\/j.rmed.2015.08.014 (2015).","journal-title":"Respir. Med."},{"key":"12314_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.resinv.2015.11.003","volume":"54","author":"M Hayashida","year":"2016","unstructured":"Hayashida, M. et al. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. Respir. Investig. 54, 193\u2013200. https:\/\/doi.org\/10.1016\/j.resinv.2015.11.003 (2016).","journal-title":"Respir. Investig."},{"key":"12314_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1378\/chest.126.6.1867","volume":"126","author":"AM Taveira-DaSilva","year":"2004","unstructured":"Taveira-DaSilva, A. M., Stylianou, M. P., Hedin, C. J., Hathaway, O. & Moss, J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126, 1867\u20131874. https:\/\/doi.org\/10.1378\/chest.126.6.1867 (2004).","journal-title":"Chest"},{"key":"12314_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02066-2018","author":"N Gupta","year":"2019","unstructured":"Gupta, N. et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02066-2018 (2019).","journal-title":"Eur. Respir. J."},{"key":"12314_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00408-012-9419-3","volume":"191","author":"N Oprescu","year":"2013","unstructured":"Oprescu, N., McCormack, F. X., Byrnes, S. & Kinder, B. W. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung 191, 35\u201342. https:\/\/doi.org\/10.1007\/s00408-012-9419-3 (2013).","journal-title":"Lung"},{"key":"12314_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/resp.12430","volume":"20","author":"W Hasegawa","year":"2015","unstructured":"Hasegawa, W. et al. Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in Japan. Respirology 20, 160\u2013165. https:\/\/doi.org\/10.1111\/resp.12430 (2015).","journal-title":"Respirology"},{"key":"12314_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","volume":"194","author":"FX McCormack","year":"2016","unstructured":"McCormack, F. X. et al. Official American Thoracic Society\/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am. J. Respir. Crit. Care Med. 194, 748\u2013761. https:\/\/doi.org\/10.1164\/rccm.201607-1384ST (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12314_CR21","doi-asserted-by":"publisher","first-page":"200007","DOI":"10.1183\/20734735.0007-2020","volume":"16","author":"AM O'Mahony","year":"2020","unstructured":"O\u2019Mahony, A. M., Lynn, E., Murphy, D. J., Fabre, A. & McCarthy, C. Lymphangioleiomyomatosis: a clinical review. Breathe (Sheff) 16, 200007. https:\/\/doi.org\/10.1183\/20734735.0007-2020 (2020).","journal-title":"Breathe (Sheff)"},{"key":"12314_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccm.2016.04.002","volume":"37","author":"SR Johnson","year":"2016","unstructured":"Johnson, S. R., Taveira-DaSilva, A. M. & Moss, J. Lymphangioleiomyomatosis. Clin. Chest. Med. 37, 389\u2013403. https:\/\/doi.org\/10.1016\/j.ccm.2016.04.002 (2016).","journal-title":"Clin. Chest. Med."},{"key":"12314_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13023-018-0946-8","volume":"13","author":"HY Yoon","year":"2018","unstructured":"Yoon, H. Y., Hwang, J. J., Kim, D. S. & Song, J. W. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis. Orphanet J. Rare Dis. 13, 204. https:\/\/doi.org\/10.1186\/s13023-018-0946-8 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"12314_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00005792-199909000-00004","volume":"78","author":"T Urban","year":"1999","unstructured":"Urban, T. et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d\u2019Etudes et de Recherche sur les Maladies \u201cOrphelines\u201d Pulmonaires (GERM\"O\"P). Medicine (Baltimore) 78, 321\u2013337. https:\/\/doi.org\/10.1097\/00005792-199909000-00004 (1999).","journal-title":"Medicine (Baltimore)"},{"key":"12314_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup, H., Krueger, D. A., International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 243\u2013254. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.001 (2013).","journal-title":"Pediatr. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12314-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:31:38Z","timestamp":1669347098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12314-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12314"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12314-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"1 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8260"}}